Scientific Advisory Board
Prof. Dr. Alexander Eggermont, Institut Gustave Roussy, Paris, France
Alexander Eggermont is a specialist in immunotherapy research and treating melanomas and sarcomas as well as in basic research in tumor pathophysiology and immunology. He is General Director of the Institut de Cancérologie Gustave Roussy (IGR, Villejuif), Professor of Surgical Oncology and Professor of International Networking in Cancer Research at the Erasmus University Medical Centre in Rotterdam and holds the ‘Joseph Maisin Chair in Oncology at the Catholic University of Leuven in Belgium. In addition, he is President of the European Academy of Cancer Sciences, and current Chair of the Adjuvant Therapy Committee EORTC Melanoma Group, placing him at a prominent position for dissemination of IACT results to the scientific community and the cancer therapeutic field.
Prof. Dr. Christoph Huber, University of Mainz, Mainz, Germany
Christoph Huber is an internationally recognized clinical researcher in the area of cancer immunotherapy. In addition, he is active in translation and management of science. He is co-founder of several Biotech-companies (Immungenix, Ganymed Pharmaceuticals, BioNTech), advisor of several small and large pharmaceutical companies and since 2002 chairs the International Association for Cancer Immunotherapy CIMT. Dr. Huber is member and advisor of numerous European funding organizations, including the German research foundation, the Experimental Cancer Medicine Program der CCR-UK and ISREC of the Swiss National Science Foundation). His experience in translation of scientific results, his connections to funding organizations and pharmaceutical companies and his position in the leading European cancer immunotherapy association make him an ideal partner for supporting IACT in the acquisition of additional funding and capital and in advising on exploitation and translation of results, as well as in dissemination to the scientific field of cancer immunotherapy.
Prof. Dr. Cornelis Melief, Leiden University Medical Center, Leiden, The Netherlands
Cornelis (Kees) Melief is professor of internal medicine specialized in cancer immunotherapy at Leiden University Medical Center, The Netherlands. Since 2008 he is also Chief Scientific Officer (CSO) of ISA Pharmaceuticals, a small biotech company specializing in development of synthetic long peptide vaccines. He strongly contributed to the field of cancer immunotherapy for many years. His work in immunotherapy of tumors with synthetic long peptides (SLP) led to the implementation of clinical trials in patients. Recently clinical effectiveness was shown in the treatment of patients with established lesions caused by high risk human papilloma virus type 16. His long term experience in the field of cancer immunotherapy and his experience in translating immunotherapeutic approaches into the clinic and into commercial applications make his an ideal advisor for IACT and his strong connections in the field will expedite the dissemination of IACT results.
Prof. Dr. Laurence Zitvogel, Institut Gustave Roussy, Paris, France
Laurence Zitvogel is director of the Center for Clinical Investigation in Biotherapies (Inserm) and full professor that the University of Paris in France. Dr. Zitvogel has been actively contributing to the field of cancer immunology and immunotherapy, bringing together basic and translational research, including the design of cancer therapies through combined animal studies and phase I patient trials. Prof. Zitvogel is widely considered an expert on the application of immunotherapeutics in conjunction with cytostatic drugs, a therapeutuic concept that is of pivotal interest to IACT consortium. She is member of numerous advisory boards of academic institutes and biotech companies, and is editor in chief of the recently (2012) founded journal Oncoimmunology, which is focused on cancer immunotherapy and has rapidly developed into one of the main communication platforms for European scientsist working in this field.